Top-rated US medical centers for CAR-T cell therapy: A Review of Clinical Capabilities and Institutional Research Leadership

The Clinical Landscape of CAR-T Cell Therapy

Chimeric Antigen Receptor (CAR) T-cell therapy represents a sophisticated advancement in immunotherapy, utilizing a patient’s own genetically engineered immune cells to identify and neutralize malignant cells 1, 2. Because this treatment requires precise laboratory manufacturing and specialized medical monitoring-particularly for managing complex inflammatory responses like cytokine release syndrome (CRS)-it is predominantly administered at large, highly specialized academic medical centers 4, 11. Eligibility for these advanced therapies is generally reserved for patients with specific relapsed or refractory hematologic malignancies who have exhausted conventional lines of treatment 2, 4.

Foundational Leaders in Cellular Immunotherapy

Penn Medicine is frequently cited as a central hub for this technology, having pioneered research that led to the first FDA-approved CAR-T cell treatment in 2017 1, 5. The institution has performed more than 760 CAR-T infusions and continues to investigate next-generation products to enhance treatment efficacy 4. Similarly, the OHSU Knight Cancer Institute has been at the forefront of long-term survival analysis, co-leading foundational clinical trials that have demonstrated lasting remissions in high-risk lymphoma populations years after the initial therapy 6.

Geographic Distribution and Specialized Programs

Accessibility to CAR-T services has expanded as regional health systems integrate these complex cellular therapy units into their oncology networks. For instance, the Northwell Cancer Institute recently established CAR-T capabilities on Long Island, focusing on patients with relapsed multiple myeloma 7. In Charleston, South Carolina, Roper St. Francis Healthcare has implemented its own cellular therapy program, citing the importance of keeping advanced precision care available within the local community to reduce the need for patient travel 9. These sites often work in coordination with established hematology departments to provide the necessary multi-disciplinary support 8.

Pediatric and Advanced Oncology Centers

Children’s hospitals and specialized oncology centers have been early adopters of CAR-T protocols due to the specific needs of younger patient populations. UCSF Benioff Children’s Hospitals, for example, were among the first in California to provide CAR-T cell therapy for children outside of a formal clinical trial setting 2. These facilities typically emphasize the management of acute side effects and the transition from intensive chemotherapy to personalized immunotherapy for conditions such as acute lymphoblastic leukemia 2.

Regulatory Oversight and Research Innovation

The development of new CAR-T therapies remains heavily regulated, with many major medical centers maintaining dedicated Investigational New Drug (IND) clearance pathways to advance their own proprietary technologies. The University of Colorado Anschutz Gates Institute recently achieved a significant milestone by receiving FDA clearance for a campus-developed CAR-T therapy targeted at aggressive leukemia 10. This underscores the trend of academic centers not only administering existing therapies but actively engineering new molecular targets, such as CD64, to address treatment resistance in high-risk patients 10.

Considerations for Treatment Access

Patients and providers must consider several factors before pursuing CAR-T therapy, including rigorous eligibility criteria and the significant logistics involved in the apheresis collection process 2, 3. Once cells are collected, they are shipped to specialized labs for genetic reprogramming before being returned for infusion 3, 7. Because of these requirements, candidates are typically assessed by comprehensive cancer centers that have the infrastructure for post-infusion monitoring, including specialized intensive care for potential toxicities 4, 8.

Sources

1. Penn Medicine, 'CAR T Cell Therapy'
2. UCSF Benioff Children's Hospitals, 'CAR T-Cell Therapy'
3. WVU Cancer Institute, 'CAR T-cell Therapy'
4. Penn Medicine, 'The next frontier for CAR T cell therapy in blood cancers'
5. Penn Medicine, 'Cell and Gene Therapy'
6. OHSU News, 'OHSU study: CAR-T therapy shows long-term survival for patients with lymphoma'
7. Northwell Health, 'CAR T-cell therapy offers new hope for myeloma patients'
8. Sharp HealthCare, 'Innovative CAR-T therapy brings new hope to cancer patients'
9. Roper St. Francis Healthcare, 'Trailblazing cancer care: CAR T-cell therapy arrives at Roper St. Francis Healthcare'
10. University of Colorado Anschutz, 'The University of Colorado Anschutz Gates Institute Achieves First-in-U.S. FDA Clearance'
11. General Industry Research, 'Academic medical centers as hubs for cellular therapy'